PACS Group, Inc.
PACS is growing fast and raising guidance, but the stock already discounts much of that momentum while leverage, investigations, and internal-control remediation cap conviction.
PACS is executing well enough to justify investor attention. The business is not just posting headline growth from acquisitions. In Q2 2026, same-store occupancy improved 150 bps to 90.6%, skilled mix improved, and adjusted EBITDA increased 25% y/y on 9.1% revenue growth. That is the kind of operating leverage that matters in this industry. Management then raised FY2026 revenue guidance to $5.75B-$5.85B and adjusted EBITDA guidance to $640M-$660M, and the updated outlook includes only a modest contribution from the 20 Eduro Texas facilities acquired on August 1, while the remaining 14 facilities are not yet reflected. There is real earnings power still building into the model.
The problem is that the stock is no longer cheap enough to ignore the risk stack. At $44.25, PACS trades at 26.04x earnings, well above the 18.0x peer average, even though this is still a low-margin operator with 5.6% FY2025 operating margin and 2.9% net margin. The market cap is $7.7B, the share price is already 22.2% above the 200-day average, and the stock is only 10.6% below the 52-week high after a sharp 16.45% move in three months. That setup can keep working if the company keeps beating, but it is not the kind of starting point that supports high-conviction chasing.
What the case depends on from here is specific. First, PACS needs to show that occupancy and skilled mix gains are sustainable across the broader portfolio, including the 106 new/ramping facilities. Second, the Eduro transactions need to close and ramp without disrupting the margin profile, especially since Q2 EBITDA margin of 9.2% was already 50 bps below Q1. Third, non-operating risk must shrink, not grow. Ongoing investigations and year-end remediation of material weaknesses matter because this company is also carrying a strained reported balance-sheet profile, including Debt/Equity of 2.93x, Debt/EBITDA of 8.89x, and a 0.91 current ratio.
That mix supports a neutral stance. PACS is not broken. In fact, the business may be headed into another leg of earnings growth. But at this price, investors are being asked to underwrite not just continued execution, but also a cleaner legal and governance narrative. Until that discount rate comes down, the stock looks like a story to monitor for confirmation rather than one to press aggressively.
Occupancy and skilled mix keep improving, the remaining 14 Eduro facilities close smoothly, and legal/control concerns fade enough for growth to dominate valuation.
Raised FY2026 guidance is delivered, Eduro closings add measured upside, and execution supports a modest advance despite risk overhang.
Investigations drag on, margin stalls near the 9.2% Q2 EBITDA margin, and the stock compresses closer to lower-end peer multiples.
Quant call (HOLD) diverges from analyst consensus (Strong Buy: 4 buy / 0 hold / 0 sell) — resolve explicitly.
We suffer more often in imagination than in reality.
Forward earnings power is improving faster than trailing numbers show, supported by FY2026 adjusted EBITDA guidance of $640M-$660M and occupancy at 90.6%, but the market is already paying 26.04x earnings for a business with unresolved investigations and a weak reported leverage profile. The moat today is operational, local market density, referral relationships, and know-how in improving underperforming facilities, but over 3-5 years its durability will depend more on reimbursement execution and compliance discipline than on technology. AI is a modest help, not a core edge, mainly through labor scheduling, documentation, and revenue-cycle efficiency rather than demand creation, so it should aid margins incrementally but is unlikely to transform the multiple. Regulation remains the real swing factor because supplemental payments are excluded from guidance and legal overhang can outweigh operating progress.
- FY2026 revenue guidance of $5.75B-$5.85B implies continued scale-up from $5.3B FY2025 revenue
- Adjusted EBITDA guidance of $640M-$660M was raised by $35M at both ends after Q2
- P/E of 26.04x versus 18.0x peer average leaves less room for error given Debt/EBITDA of 8.89x and ongoing investigations
- Q2 2026 revenue grew 9.1% y/y and adjusted EBITDA rose 25% y/y, showing cost discipline and operating leverage.
- Same-store occupancy increased 150 bps to 90.6%, while skilled mix improved 100 bps overall, supporting better earnings quality than simple acquisition-led growth.
- Management raised FY2026 revenue guidance by $100M at both ends and adjusted EBITDA guidance by $35M at both ends, with only a modest contribution from 20 Eduro Texas facilities and 14 remaining facilities not yet included.
- 106 new/ramping facilities provide an embedded growth runway beyond the current same-store gains.
- Debt/Equity is 2.93x, Debt/EBITDA is 8.89x, and the current ratio is 0.91, which is a weak balance-sheet profile for a business facing legal and reimbursement uncertainty.
- Q2 EBITDA margin was 9.2%, down 50 bps q/q from 9.7% in Q1, a reminder that margin expansion is not linear even in a favorable operating quarter.
- Government investigations remain unresolved, and management said material weaknesses remediation is only expected to be on track by year-end 2026, which can keep the valuation capped.
- The stock is only 10.6% below its 52-week high of $49.49 after a 16.45% gain in 3 months, so the setup is less forgiving if execution slips.
| Metric | Value | Context |
|---|---|---|
| Current price | $44.25 | Reference price for rating and scenario framework |
| Quant price target | $54.46 | 23.1% upside vs current, Low confidence, basis earnings_growth_blend |
| FY2025 revenue | $5.3B | 130.5% YoY growth |
| FY2025 EPS | $1.23 | 66.7% YoY growth |
| FY2025 operating margin | 5.6% | Up from 3.0% in prior FY |
| FY2026 revenue guidance | $5.75B-$5.85B | Raised by $100M on both ends, roughly 10% growth |
| FY2026 adjusted EBITDA guidance | $640M-$660M | Raised by $35M on both ends, roughly 29% growth |
| Valuation | P/E 26.04x | P/S 1.26x | P/B 6.3x | P/E above 18.0x peers, P/S below 2.3x peers |
| Leverage and liquidity | Debt/Equity 2.93x | Debt/EBITDA 8.89x | Current ratio 0.91 | Weak reported financial-health profile despite call commentary on liquidity |
| Q2 2026 operating markers | Revenue +9.1% | Adj. EBITDA +25% | EBITDA margin 9.2% | Margin up 190 bps y/y, down 50 bps q/q |
| 52-week position | $7.50-$49.49 | Current price is -10.6% vs high and 22.2% above 200-day average |
The biggest risk is that unresolved investigations and control remediation collide with a leveraged capital structure, with Debt/EBITDA at 8.89x and Financial Health at 19/100, causing a de-rating even if operations remain decent.
The next catalyst is Q3 results / earnings on November 25, 2026, especially whether PACS closes the remaining 14 Eduro facilities and again raises FY2026 guidance.
Ownership is unusually tight, with insiders holding 71.4% and the top 3 institutions holding 28.0%, which limits float and can amplify moves. Short interest is 8.00%, or 3.82M shares, with 4.4 days-to-cover, meaningful but not extreme, and it fell 15.6%, suggesting some bearish pressure has already eased. Options positioning is described as positive GEX, which can damp near-term volatility, but the setup still looks more momentum-supported than washed out given the stock is just 10.6% below its high.
Revenue is driven by same-store occupancy, skilled mix, and acquisitions, with 106 new/ramping facilities still contributing to embedded growth.
20 Texas facilities closed on Aug. 1, 2026, with a modest FY2026 contribution in guidance and 14 remaining facilities expected in Q3-Q4.
Business exposure is domestic and tied to U.S. care facility demand, reimbursement conditions, and state-level operating execution.
PACS posted a strong Q2 and raised FY26 revenue and EBITDA guidance.
As we look at the back half of the year, we expect to continue to perform at a high level, and therefore, we're increasing both our full year revenue and our adjusted EBITDA guidance.
We're increasing our full year revenue guidance to a range of $5.75 billion to $5.85 billion, which is up $100 million on both ends of the range from our previous range of $5.65 billion to $5.75 billion.
We're also increasing our adjusted EBITDA guidance to a range of $640 million to $660 million, which is up $35 million on both ends of the range from our previous range of $605 million to $625 million.
Revenue increased 9.1% in the second quarter, while adjusted EBITDA grew 25% compared to the prior year.
Our updated guidance, therefore, includes a modest contribution from the 20 Texas facilities that we acquired from Eduro on August 1, for the portion of the year in which we'll operate those facilities. However, the remaining 14 facilities associated with the Eduro transaction are not reflected in our current guidance because those acquisitions have not yet closed.
PACS' edge is operating density and turnaround capability in skilled nursing facilities, evidenced by same-store occupancy up 150 bps to 90.6% and adjusted EBITDA up 25% y/y in Q2. That moat is real but not impregnable because barriers are execution, referral relationships, and compliance systems rather than proprietary technology. Its durability improves if PACS converts the 106 new/ramping facilities into stable margin contributors without regulatory setbacks.
Capital allocation is currently growth-first. PACS generated only $0.1B of FCF in FY2025, with no buybacks, no dividend, and no disclosed capex in the deep-dive data, so equity holders are relying on reinvestment and acquisitions rather than direct cash returns. That is sensible for a consolidator, but with Debt/Equity at 2.93x and legal uncertainty, discipline matters more than speed.
Rated HOLD, Low conviction. PACS has a credible growth story, and the raised FY2026 guidance plus occupancy and mix gains argue that earnings power is still moving up. But the stock already reflects a fair amount of that good news, while leverage, governance cleanup, and unresolved investigations keep the downside meaningful. A move to BUY would require either a cheaper entry point or more evidence that the legal and control overhang is fading without damaging margins. A move to SELL would require evidence that margin gains are stalling or that the investigations are becoming financially material.
≣ Full research note tap to expand
Executive Summary
HOLD, Low conviction. PACS rates a HOLD at Low conviction. The operating story is real, with FY2025 revenue up 130.5%, FY2026 revenue guidance at $5.75B-$5.85B, and FY2026 adjusted EBITDA guidance at $640M-$660M, but the stock at $44.25 already sits 22.2% above its 200-day average and 26.04x earnings, above the 18.0x peer average. The balance between strong execution and elevated company-specific risk keeps the stance neutral despite the quant engine's $54.46 target.
Investment Thesis
PACS is executing well enough to justify investor attention. The business is not just posting headline growth from acquisitions. In Q2 2026, same-store occupancy improved 150 bps to 90.6%, skilled mix improved, and adjusted EBITDA increased 25% y/y on 9.1% revenue growth. That is the kind of operating leverage that matters in this industry. Management then raised FY2026 revenue guidance to $5.75B-$5.85B and adjusted EBITDA guidance to $640M-$660M, and the updated outlook includes only a modest contribution from the 20 Eduro Texas facilities acquired on August 1, while the remaining 14 facilities are not yet reflected. There is real earnings power still building into the model.
The problem is that the stock is no longer cheap enough to ignore the risk stack. At $44.25, PACS trades at 26.04x earnings, well above the 18.0x peer average, even though this is still a low-margin operator with 5.6% FY2025 operating margin and 2.9% net margin. The market cap is $7.7B, the share price is already 22.2% above the 200-day average, and the stock is only 10.6% below the 52-week high after a sharp 16.45% move in three months. That setup can keep working if the company keeps beating, but it is not the kind of starting point that supports high-conviction chasing.
What the case depends on from here is specific. First, PACS needs to show that occupancy and skilled mix gains are sustainable across the broader portfolio, including the 106 new/ramping facilities. Second, the Eduro transactions need to close and ramp without disrupting the margin profile, especially since Q2 EBITDA margin of 9.2% was already 50 bps below Q1. Third, non-operating risk must shrink, not grow. Ongoing investigations and year-end remediation of material weaknesses matter because this company is also carrying a strained reported balance-sheet profile, including Debt/Equity of 2.93x, Debt/EBITDA of 8.89x, and a 0.91 current ratio.
That mix supports a neutral stance. PACS is not broken. In fact, the business may be headed into another leg of earnings growth. But at this price, investors are being asked to underwrite not just continued execution, but also a cleaner legal and governance narrative. Until that discount rate comes down, the stock looks like a story to monitor for confirmation rather than one to press aggressively.
Key Metrics
| Metric | Value | Context | ||
|---|---|---|---|---|
| Current price | $44.25 | Reference price for rating and scenario framework | ||
| Quant price target | $54.46 | 23.1% upside vs current, Low confidence, basis earnings_growth_blend | ||
| FY2025 revenue | $5.3B | 130.5% YoY growth | ||
| FY2025 EPS | $1.23 | 66.7% YoY growth | ||
| FY2025 operating margin | 5.6% | Up from 3.0% in prior FY | ||
| FY2026 revenue guidance | $5.75B-$5.85B | Raised by $100M on both ends, roughly 10% growth | ||
| FY2026 adjusted EBITDA guidance | $640M-$660M | Raised by $35M on both ends, roughly 29% growth | ||
| Valuation | P/E 26.04x | P/S 1.26x | P/B 6.3x | P/E above 18.0x peers, P/S below 2.3x peers |
| Leverage and liquidity | Debt/Equity 2.93x | Debt/EBITDA 8.89x | Current ratio 0.91 | Weak reported financial-health profile despite call commentary on liquidity |
| Q2 2026 operating markers | Revenue +9.1% | Adj. EBITDA +25% | EBITDA margin 9.2% | Margin up 190 bps y/y, down 50 bps q/q |
| 52-week position | $7.50-$49.49 | Current price is -10.6% vs high and 22.2% above 200-day average |
Financial Strength
The operating engine is improving faster than the balance sheet would suggest, but the financial profile is still the weak link. PACS generated only $0.1B of FCF in FY2025 on $5.3B of revenue, which is thin relative to a $3.3B debt load. Reported leverage looks stretched at 8.89x Debt/EBITDA, and the 0.91 current ratio leaves little room for error if legal, reimbursement, or integration issues emerge. The positive offset is that margins are moving the right way, with operating margin improving to 5.6% in FY2025 and Q2 showing solid year-over-year EBITDA expansion, so the balance sheet can heal if execution stays clean.
Competitive Position
PACS' edge is operating density and turnaround capability in skilled nursing facilities, evidenced by same-store occupancy up 150 bps to 90.6% and adjusted EBITDA up 25% y/y in Q2. That moat is real but not impregnable because barriers are execution, referral relationships, and compliance systems rather than proprietary technology. Its durability improves if PACS converts the 106 new/ramping facilities into stable margin contributors without regulatory setbacks.
Management & Guidance
Management has earned some credibility recently. The last two quarters delivered EPS beats of +19.0% and +17.3%, and after Q2 2026 the company raised both revenue and EBITDA guidance. CFO Carey Hendrickson said, "As we look at the back half of the year, we expect to continue to perform at a high level, and therefore, we're increasing both our full year revenue and our adjusted EBITDA guidance." That said, the track record is not spotless, with notable misses in 2025-11-19 (-28.9%) and 2026-02-26 (-10.4%), so guidance deserves respect but not a full benefit of the doubt, especially while investigations remain open and material weakness remediation is still targeted for year-end.
Segment Analysis
- Skilled nursing / care facilities (Not disclosed): Revenue is driven by same-store occupancy, skilled mix, and acquisitions, with 106 new/ramping facilities still contributing to embedded growth.
- Texas Eduro acquisition facilities (20 closed, 14 pending): 20 Texas facilities closed on Aug. 1, 2026, with a modest FY2026 contribution in guidance and 14 remaining facilities expected in Q3-Q4.
- United States (Essentially 100%): Business exposure is domestic and tied to U.S. care facility demand, reimbursement conditions, and state-level operating execution.
Capital Allocation
Capital allocation is currently growth-first. PACS generated only $0.1B of FCF in FY2025, with no buybacks, no dividend, and no disclosed capex in the deep-dive data, so equity holders are relying on reinvestment and acquisitions rather than direct cash returns. That is sensible for a consolidator, but with Debt/Equity at 2.93x and legal uncertainty, discipline matters more than speed.
Positioning & Flows
Ownership is unusually tight, with insiders holding 71.4% and the top 3 institutions holding 28.0%, which limits float and can amplify moves. Short interest is 8.00%, or 3.82M shares, with 4.4 days-to-cover, meaningful but not extreme, and it fell 15.6%, suggesting some bearish pressure has already eased. Options positioning is described as positive GEX, which can damp near-term volatility, but the setup still looks more momentum-supported than washed out given the stock is just 10.6% below its high.
Bull Case
- Q2 2026 revenue grew 9.1% y/y and adjusted EBITDA rose 25% y/y, showing cost discipline and operating leverage.
- Same-store occupancy increased 150 bps to 90.6%, while skilled mix improved 100 bps overall, supporting better earnings quality than simple acquisition-led growth.
- Management raised FY2026 revenue guidance by $100M at both ends and adjusted EBITDA guidance by $35M at both ends, with only a modest contribution from 20 Eduro Texas facilities and 14 remaining facilities not yet included.
- 106 new/ramping facilities provide an embedded growth runway beyond the current same-store gains.
Bear Case
- Debt/Equity is 2.93x, Debt/EBITDA is 8.89x, and the current ratio is 0.91, which is a weak balance-sheet profile for a business facing legal and reimbursement uncertainty.
- Q2 EBITDA margin was 9.2%, down 50 bps q/q from 9.7% in Q1, a reminder that margin expansion is not linear even in a favorable operating quarter.
- Government investigations remain unresolved, and management said material weaknesses remediation is only expected to be on track by year-end 2026, which can keep the valuation capped.
- The stock is only 10.6% below its 52-week high of $49.49 after a 16.45% gain in 3 months, so the setup is less forgiving if execution slips.
Valuation & Price Target
Engine price target $54.46 (+23.1% vs current), Low confidence.
- P/E Multiple: $22.52 (28% weight)
- PEG (growth-adjusted): $91.8 (17% weight)
- P/S Multiple: $78.6 (20% weight)
- Quality-adjusted: $43.54 (20% weight)
The rating stays at HOLD, aligning with the quant baseline, even though the engine's $54.46 target implies 23.1% upside. The reason is confidence, not arithmetic. PACS does have strong forward momentum, with FY2026 revenue guidance of $5.75B-$5.85B, adjusted EBITDA guidance of $640M-$660M, and two straight sizable EPS beats of +19.0% and +17.3%. But the valuation already sits at 26.04x P/E versus a peer average of 18.0x, peer dispersion is wide at 5.5x, and company-specific risk is high enough to keep the target from supporting a more aggressive call: Debt/EBITDA 8.89x, current ratio 0.91, ongoing investigations, and material weakness remediation still in process. Sell-side consensus is Strong Buy (4 buy / 0 hold / 0 sell), but that is low-signal context here and does not outweigh the balance-sheet and governance overhangs.
Risk Assessment
Risk score 53/100 (Moderate). The biggest risk is that unresolved investigations and control remediation collide with a leveraged capital structure, with Debt/EBITDA at 8.89x and Financial Health at 19/100, causing a de-rating even if operations remain decent.
The Bottom Line
Rated HOLD, Low conviction. PACS has a credible growth story, and the raised FY2026 guidance plus occupancy and mix gains argue that earnings power is still moving up. But the stock already reflects a fair amount of that good news, while leverage, governance cleanup, and unresolved investigations keep the downside meaningful. A move to BUY would require either a cheaper entry point or more evidence that the legal and control overhang is fading without damaging margins. A move to SELL would require evidence that margin gains are stalling or that the investigations are becoming financially material.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr